Online inquiry

IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7114MR)

This product GTTS-WQ7114MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL6&IL6R gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000600.5; NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569; 3570
UniProt ID P05231; P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ7114MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13035MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ2343MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AME-133v
GTTS-WQ6563MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DC-1630423
GTTS-WQ8872MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ2549MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ3511MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAN-2401
GTTS-WQ14749MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ6356MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CSL-362-AML
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW